IBP-9414

Unassigned

New Medicines

Necrotising enterocolitis in premature infants

Information

Bacterial replacement
Infant Bacterial Therapeutics (IBT)
Infant Bacterial Therapeutics (IBT)

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Bacterial product, Lactobacillus reuteri
A disease of prematurity, nearly 12% of infants born weighing less than 1500 g will develop NEC and about 30% of these infants will not survive [2].
Necrotising enterocolitis in premature infants
Oral